(Q54573577)

1 June 2018

title

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. (English)

1 reference

1 June 2018

2

Srdan Verstovsek

1 reference

1 June 2018

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

1 June 2018

language of work or name

English

0 references

publication date

15 July 2011

1 reference

1 June 2018

published in

Cancer

1 reference

1 June 2018

volume

118

1 reference

1 June 2018

issue

4

1 reference

1 June 2018

page(s)

870-877

1 reference

1 June 2018

The chronic myeloproliferative disorders: clonality and clinical heterogeneity

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Choosing between stem cell therapy and drugs in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

The haematocrit and platelet target in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Polycythemia vera: myths, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Pathogenesis and management of essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

How I treat patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Transcriptional responses to polypeptide ligands: the JAK-STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

How I treat symptomatic splenomegaly in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Advances in the therapy of chronic idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Sex, splenectomy, and myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Pathogenesis of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

How I treat myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

A phase-2 trial of low-dose pomalidomide in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

inferred from DOI database lookup

7 January 2021

based on heuristic

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

inferred from DOI database lookup

7 January 2021

based on heuristic

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26359

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26359

1 reference

1 June 2018

1 reference

1 June 2018